WaveMan
WaveMan · Company
KROS · Keros Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KROS Keros Therapeutics (KROS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001664710
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
60
13F, latest reported quarter

What the filings say about KROS

Insiders, 180 days
-$149.5K net sold
1 buyer · 7 sellers · 12% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.7K
1 notice

Keros Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Keros Therapeutics, Inc. insiders sold a net $149.5K of stock across 172 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lerner Lorena Raquel
Chief Scientific Officer
SELL
2026-08-20 SECtraded 2026-08-18
3,568
$36.7K
+2.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 18, 2026.
  • The trade is 12.9% of the 27,559 shares held after it.
  • 3 other insiders sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lerner Lorena Raquel sold about $36.7K of KROS on Aug 18, 2026; 3 other insiders sold within 30 days and 60 funds added in the latest 13F quarter.
Cho Esther
Chief Legal Officer
SELL
2026-08-20 SECtraded 2026-08-18
4,485
$46.2K
+2.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 18, 2026.
  • The trade is 12.5% of the 35,770 shares held after it.
  • 3 other insiders sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Cho Esther sold about $46.2K of KROS on Aug 18, 2026; 3 other insiders sold within 30 days and 60 funds added in the latest 13F quarter.
Newton Charles W.
Director
SELL
2026-08-20 SECtraded 2026-08-18
551
$5.7K
+2.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 11, 2026.
  • The trade is 4.5% of the 12,114 shares held after it.
  • 3 other insiders sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Newton Charles W. sold about $5.7K of KROS under a 10b5-1 plan on Aug 18, 2026; 3 other insiders sold within 30 days and 60 funds added in the latest 13F quarter.
Tanini Annita
Corp. Controller & VP, Finance
SELL
2026-08-20 SECtraded 2026-08-18
1,224
$12.6K
+2.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.7% of the 45,144 shares held after it.
  • 3 other insiders sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Corp. Controller & VP, Finance Tanini Annita sold about $12.6K of KROS on Aug 18, 2026; 3 other insiders sold within 30 days and 60 funds added in the latest 13F quarter.
BIENAIME JEAN JACQUES
Director
BUY
2026-08-19 SECtraded 2026-08-17
1,000
$10.3K
+3.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 15, 2026.
  • +1.5% median (-1.8% mean) 90-day return after 5 previous buys.
  • The trade is 5.1% of the 19,592 shares held after it.
  • No other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BIENAIME JEAN JACQUES bought about $10.3K of KROS on Aug 17, 2026; 60 funds added in the latest 13F quarter.
172 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 167 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$149.5K over 180 days
-$90.9K over 90 days
more than 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
60 funds bought in last quarter
more than 51% of Pharma & Biotech
Revenue
+6775.0% year over year
more than 98% of Pharma & Biotech
Margin
35.7% net margin
more than 92% of Pharma & Biotech
Buybacks
$375.0M repurchased, FY to 2025-12-31
more than 86% of Pharma & Biotech
Short interest
6.5% of the float short (float per yahoo 2026-10-26) · 5.6 days to cover · settled 2026-09-30
more than 55% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KROS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.5%12M
-36%-11%+15%+40%2025-102025-122026-022026-042026-062026-082026-10 2026-02-19 · Seehra Jasbir sold $113.4K2026-02-18 · Cho Esther sold $77.6K2026-02-18 · Regnante Keith sold $77.5K2026-02-18 · Lerner Lorena Raquel sold $63.3K2026-08-18 · Cho Esther sold $46.2K2026-08-18 · Lerner Lorena Raquel sold $36.7K2026-06-04 · Farzan Nima sold $28.2K2026-06-04 · Knowles Julius sold $28.2K2026-06-04 · Seth Alpna sold $28.1K2026-03-09 · BIENAIME JEAN JACQUES bought $22.4K2026-08-18 · Tanini Annita sold $12.6K2026-04-15 · BIENAIME JEAN JACQUES bought $11.7K2026-07-15 · BIENAIME JEAN JACQUES bought $10.6K2026-05-15 · BIENAIME JEAN JACQUES bought $10.6K2026-08-17 · BIENAIME JEAN JACQUES bought $10.3K2026-06-15 · BIENAIME JEAN JACQUES bought $10.2K2026-08-18 · Newton Charles W. sold $5.7K2026-06-11 · Newton Charles W. sold $5.5K2026-08-18 · Newton Charles W. filed to sell $5.7K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KROS: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
2,820,838 sh
$30.2M
BlackRock, Inc.
2,794,217 sh
$29.9M
AQR CAPITAL MANAGEMENT LLC
967,859 sh
$10.4M
VANGUARD CAPITAL MANAGEMENT LLC
833,596 sh
$8.9M
ORBIMED ADVISORS LLC
759,155 sh
$8.1M

Congress trades in KROS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KROS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Newton Charles W.
Filed 2026-08-18
$5.7K

KROS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$802.5K position · as of 2026-06-30
0.8%
OneAscent Enhanced Small and Mid Cap ETF
$169.1K position · as of 2026-05-31
0.2%
Ultra-Small Company Market Fund
$267.5K position · as of 2026-06-30
0.2%
Federated Hermes MDT Small Cap Core Fund
$3.9M position · as of 2026-07-31
0.2%
NVIT Small Cap Value Fund
$369.6K position · as of 2026-06-30
0.2%
Federated Hermes MDT Small Cap Growth Fund
$1.2M position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
1 active
What changed recently
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
2026-10-01 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Jasbir Seehra
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$8.9M
$3.4M
$3.0M
-44%
-6%
2022
$6.5M
$710.1K
$3.3M
-32%
-10%
2021
$7.2M
-$4.5M
$2.9M
-17%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $149.5K sold by insiders over 180 days, 60 funds added last quarter, $5.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KROS financials

Revenue growth
+6775.0%
XBRL, annual
Net margin
35.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-553.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$48.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-17.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-15.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-20.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-21.7%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$244.1M$3.5M$151.0K$0
Operating income$67.6M-$210.8M-$169.9M-$114.8M
Net income$87.0M-$187.4M-$153.0M-$104.7M
EPS (diluted)2.30-5.00-5.20-4.15
Operating cash flow$107.5M-$160.9M-$124.5M-$70.1M
Cash$287.4M$559.9M$331.1M$279.0M
Buybacks$375.0M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

KROS Stock Sonar score 5/7 axes

Find similar shapesCompare

KROS ranks highest on growth (98th percentile) and profitability (72nd), and lowest on institutional and government (51st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
72
Inputs
  • Return on equity-17.2% · 73 pct, sector of 545
  • Return on assets-15.9% · 70 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-20.3% · 73 pct, sector of 576
Growth
98
Inputs
  • Revenue growth, YoY+6775% · 98 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
54
Inputs
  • Net Form 4 buying (codes P and S), 180d-$144K · 51 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
51
Inputs
  • Funds adding, latest quarter60 · 51 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
57
Inputs
  • Short interest, % of float+6.5% · 51 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.2% · 63 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KROS filings, in plain words

Are Keros Therapeutics insiders buying or selling KROS?

In the 180 days to 2026-10-27, Keros Therapeutics insiders were net sellers, a net $149.5K: $41.6K of purchases and $191.1K of sales reported on Form 4, by 1 buyer and 7 sellers.

Are there planned insider sales of KROS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $5.7K of stock; the latest, by Newton Charles W., was filed 2026-08-18.

Read the full summary

In the 180 days to 2026-10-27, Keros Therapeutics insiders were net sellers of KROS, a net $149.5K across purchases and sales reported on Form 4 by 1 buyer and 7 sellers. 12% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $5.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies